Patents by Inventor Alan M. Laties
Alan M. Laties has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8618088Abstract: The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.Type: GrantFiled: March 29, 2012Date of Patent: December 31, 2013Assignee: University of PennsylvaniaInventors: Rong Wen, Zhijun Luo, Alan M. Laties
-
Publication number: 20130338145Abstract: Provided is a method of treating or preventing age-related macular degeneration (AMD) or Stargardt's disease in a patient subject to, or symptomatic of the disease, whereby normal lysosomal pH (pHL) of compromised retinal pigment epithelium (RPE) cells of the eye is restored, or abnormally elevated pHL is reacidified, thus decreasing or preventing damaging accumulations of lipofuscin debris or photoreceptor waste products. Further provided is a method for restoring photoreceptors to the eye of a patient subject to, or symptomatic of reduced photoreceptor activity or lipofuscin accumulation in RPE cells. By these methods D5 dopamine receptor (D5DR) agonists are administered to stimulate D5DR activity of compromised RPE cells, thereby regulating and reacidifying lysosomal pH (pHL) by a D5 dopamine receptor-(D5DR)-mediated pathway, without altering baseline maintenance.Type: ApplicationFiled: March 15, 2013Publication date: December 19, 2013Inventors: Claire H. Mitchell, Alan M. Laties
-
Publication number: 20120190705Abstract: The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.Type: ApplicationFiled: March 29, 2012Publication date: July 26, 2012Inventors: Rong Wen, Zhijun Luo, Alan M. Laties
-
Patent number: 8163726Abstract: The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.Type: GrantFiled: September 18, 2003Date of Patent: April 24, 2012Assignee: University of PennsylvaniaInventors: Rong Wen, Zhijun Luo, Alan M. Laties
-
Publication number: 20090036479Abstract: The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.Type: ApplicationFiled: October 2, 2008Publication date: February 5, 2009Applicant: University of PennsylvaniaInventors: Rong Wen, Zhijun Luo, Alan M. Laties
-
Publication number: 20020119974Abstract: Methods for the prevention and treatment of diseases and conditions of the eye including, but are not limited to: central retinal artery occlusion; central retinal vein occlusion; optic neuropathy including, but not limited to, anterior ischemic optic neuropathy and glaucomatous optic neuropathy; and macular (dry) degeneration are disclosed. These methods comprise administering to a patient a prophylactically or therapeutically effective amount of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type 5 inhibitor. Pharmaceutical compositions and dosage forms comprising cyclic guanosine 3′,5′-monophosphate phosphodiesterase type 5 inhibitors are also disclosed.Type: ApplicationFiled: April 19, 2002Publication date: August 29, 2002Inventor: Alan M. Laties
-
Patent number: 5637604Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a muscarinic pharmacological antagonist relatively selective for blocking the cholinergic receptors in cells of the brain, neural tissue and/or neural ganglia but less selective for blocking the cholinergic receptors of the cells of smooth muscles at the front of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is pirenzepine. Other suitable antagonists are telenzepine and o-methoxy-sila-hexocyclium.Type: GrantFiled: June 29, 1994Date of Patent: June 10, 1997Assignee: The Trustees of the University of PennsylvaniaInventors: Alan M. Laties, Richard A. Stone
-
Patent number: 5571823Abstract: A method of controlling the abnormal postnatal growth of the eye of a maturing animal which comprises the ocular administration of therapeutically effective amounts of a dopamine antagonist.Type: GrantFiled: June 22, 1993Date of Patent: November 5, 1996Assignees: The Trustees of the University of Pennsylvania, Emory UniversityInventors: Richard A. Stone, Alan M. Laties, Paul M. Iuvone
-
Patent number: 5567731Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a gamma aminobutyric acid antagonist relatively selective for GABA.sub.B receptors in the cells of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is 2-OH saclofen.Type: GrantFiled: September 27, 1994Date of Patent: October 22, 1996Assignee: The Trustees of the University of PennsylvaniaInventors: Alan M. Laties, Richard A. Stone
-
Patent number: 5461052Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a tricyclic compound, said tricyclic compound present in a carrier or diluent suitable for ocular administration. Suitable tricyclics are tertiary amines, secondary amines, and other active metabolites of tricyclic compounds.Type: GrantFiled: April 30, 1993Date of Patent: October 24, 1995Assignee: The Trustees of the University of PennsylvaniaInventors: Richard A. Stone, Alan M. Laties
-
Patent number: 5385939Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a gamma aminobutyric acid antagonist relatively selective for GABA.sub.B receptors in the cells of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is 2-OH saclofen.Type: GrantFiled: April 30, 1993Date of Patent: January 31, 1995Assignee: The Trustees of the University of PennsylvaniaInventors: Alan M. Laties, Richard A. Stone
-
Patent number: 5360801Abstract: A method of inducing axial elongation of an eye of an animal comprising contacting a first open animal eye with a cholinergic agonist, detecting the change in axial growth of the first eye, applying a known control agent in a second open animal eye, observing the results of the control agent on the second eye, and comparing the change in axial growth of the first eye with the change in axial growth of the second eye.Type: GrantFiled: January 14, 1993Date of Patent: November 1, 1994Assignee: The Trustees of The University of PennsylvaniaInventors: Alan M. Laties, Richard A. Stone
-
Patent number: 5356892Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a muscarinic pharmacological antagonist relatively selective for blocking the cholinergic receptors in cells of the brain, neural tissue and/or neural ganglia but less selective for blocking the cholinergic receptors of the cells of smooth muscles at the front of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is pirenzepine. Other suitable antagonists are telenzepine and o-methoxy-sila-hexocyclium.Type: GrantFiled: March 24, 1992Date of Patent: October 18, 1994Assignee: The Trustees of The University of PennsylvaniaInventors: Alan M. Laties, Richard A. Stone
-
Patent number: 5284843Abstract: A method of inhibiting the abnormal postnatal axial growth of the eye of a maturing animal during conditions ordinarily leading to said abnormal growth, which comprises (1) determining the neurochemical present in the retina of said eye, eg., dopamine, the concentrations of which is reduced during said conditions, and (2) administering to said eye during post natal maturation effective amounts of said neurochemical, its agonist or its antagonist.Type: GrantFiled: April 10, 1991Date of Patent: February 8, 1994Assignees: Trustees of the University of Penna., Emory UniversityInventors: Richard A. Stone, Alan M. Laties, Paul M. Iuvone
-
Patent number: 5122522Abstract: A composition for the inhibition of the abnormal postnatal axial growth of the eye of a maturing animal which comprises a pharmaceutically effective amount of a muscarinic pharmacological antagonist relatively selective for blocking the cholinergic receptors in cells of the brain, neural tissue and/or neural ganglia but less selective for blocking the cholinergic receptors of the cells of smooth muscles at the front of the eye, said antagonist present in a carrier or diluent suitable for ocular administration. A suitable antagonist is pirenzepine. Other suitable antagonists are telenzepine and o-methoxy-sila-hexocyclium.Type: GrantFiled: May 11, 1990Date of Patent: June 16, 1992Assignee: The Trustees of the University of PennsylvaniaInventors: Alan M. Laties, Richard A. Stone
-
Patent number: 5055302Abstract: A method and composition for inhibition of abnormal postnatal ocular growth are disclosed. The composition comprises vasoactive intestinal peptide (VIP), PHI or a analogue of these peptides. The method for inhibition of abnormal postnatal ocular growth comprises administering to the eye of an animal effective amount of VIP, PHI or analogue of these peptides.Type: GrantFiled: February 22, 1990Date of Patent: October 8, 1991Assignee: Trustees of the University of PennsylvaniaInventors: Alan M. Laties, Richard A. Stone
-
Patent number: 4350676Abstract: A method of using carboxyfluorescein in ophthalmic studies comprising applying of the eye an effective amount of at least one active isomer of carboxyfluorescein.Type: GrantFiled: May 21, 1981Date of Patent: September 21, 1982Inventors: Alan M. Laties, Richard A. Stone